Last reviewed · How we verify
Vesomni®
Vesomni is a combination of silodosin (alpha-1A adrenergic antagonist) and mirabegron (beta-3 adrenergic agonist) that addresses both obstructive and storage symptoms of benign prostatic hyperplasia.
Vesomni is a combination of silodosin (alpha-1A adrenergic antagonist) and mirabegron (beta-3 adrenergic agonist) that addresses both obstructive and storage symptoms of benign prostatic hyperplasia. Used for Benign prostatic hyperplasia with lower urinary tract symptoms (obstructive and storage symptoms).
At a glance
| Generic name | Vesomni® |
|---|---|
| Sponsor | Eurofarma Laboratorios S.A. |
| Drug class | Alpha-1A antagonist / Beta-3 agonist combination |
| Target | Alpha-1A adrenergic receptor; Beta-3 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
Silodosin relaxes smooth muscle in the prostate and bladder neck by blocking alpha-1A adrenergic receptors, reducing urinary obstruction. Mirabegron relaxes the detrusor muscle via beta-3 adrenergic agonism, increasing bladder capacity and reducing overactive bladder symptoms. The combination targets complementary pathways to improve both lower urinary tract obstruction and urgency/frequency symptoms.
Approved indications
- Benign prostatic hyperplasia with lower urinary tract symptoms (obstructive and storage symptoms)
Common side effects
- Retrograde ejaculation
- Headache
- Dizziness
- Hypertension
- Nasopharyngitis
Key clinical trials
- Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (PHASE3)
- Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. (BENIPRO) (PHASE3)
- EC905 Pharmacokinetic Profile Study (PHASE1)
- A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vesomni® CI brief — competitive landscape report
- Vesomni® updates RSS · CI watch RSS
- Eurofarma Laboratorios S.A. portfolio CI